Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid Syndrome

Seminars in Thrombosis and Hemostasis

Volumn 44, Issue 5, 2018, Pages 427-438

  Cohen, Hannah ^a,b   Efthymiou, Maria ^a   Gates, Carolyn ^b   Isenberg, David ^b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

antiphospholipid syndrome; direct oral anticoagulants; ischemic stroke; thromboprophylaxis; venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; CARBAMAZEPINE; DABIGATRAN; DABIGATRAN ETEXILATE; EDOXABAN; ITRACONAZOLE; KETOCONAZOLE; PHENYTOIN; RIFAMPICIN; RIVAROXABAN; THROMBIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERIAL ISCHEMIC ATTACK; ARTICLE; BRAIN ISCHEMIA; CLINICAL TRIAL (TOPIC); GASTROINTESTINAL HEMORRHAGE; HUMAN; LACTATION; MICROVASCULAR THROMBOSIS; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; SUPERFICIAL VEIN THROMBOSIS; THROMBOSIS; VENOUS THROMBOEMBOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; HUMANS; VENOUS THROMBOEMBOLISM;

EID: 85012866163     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0036-1597902     Document Type: Article

References (99)

1. Erkan D. Aguiar C. L. Andrade D., et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev: 2014; 13 06 685 696
2. Pradaxa (dabigatran) 150 mg and 110 mg hard capsules: summary of product characteristics (SPC), EU. Boehringer Ingelheim International GmBH. Available at: https://www.medicines.org.uk/emc/medicine/24839. Accessed June 2016
3. Eliquis (apixaban) 2.5 mg and 5 mg film-coated tablets film-coated tablets Summary of Product Characteristics (SPC). Bristol-Myers Squibb-Pfizer. Available at: http://www.medicines.org.uk/emc/medicine/24988. Accessed June 2016
4. Lixiana (edoxaban) 30 mg and 60 mg film-coated Tablets - Summary of Product Characteristics. Daiichi Sankyo UK Limited. Available at: https://www.medicines.org.uk/emc/medicine/30506. Accessed June 2016
5. Xarelto (rivaroxaban) 15 mg and 20 mg film-coated tablets. Summary of Product Characteristics. Bayer Pharma AG. Available at: https://www.medicines.org.uk/emc/medicine/25586. Accessed June 2016
6. Miyakis S. Lockshin M. D. Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost: 2006; 4 02 295 306
7. Cervera R. Serrano R. Pons-Estel G. J., et al; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis: 2015; 74 06 1011 1018
8. Antiphospholipid syndrome. Available at: https://rarediseases.info.nih.gov/gard/5824/antiphospholipid-syndrome/resources/1: 2016;. Accessed January 20, 2017
9. Andreoli L. Chighizola C. B. Banzato A. Pons-Estel G. J. Ramire de Jesus G. Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken): 2013; 65 11 1869 1873
10. Know VTE. International Society on Thrombosis and Haemostasis. Available at: http://www.worldthrombosisday.org/issue/vte/ Accessed June: 2016
11. Stroke Association. State of the Nation - Stroke Statistics. Available at: https://www.stroke.org.uk/sites/default/files/stroke-statistics-2015.pdf. Accessed June: 2016
12. Ruiz-Irastorza G. Egurbide M. V. Ugalde J. Aguirre C. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus. Arch Intern Med: 2004; 164 01 77 82
13. Krnic-Barrie S. O'Connor C. R. Looney S. W. Pierangeli S. S. Harris E. N. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med: 1997; 157 18 2101 2108
14. Rosove M. H. Brewer P. M. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med: 1992; 117 04 303 308
15. Khamashta M. A. Cuadrado M. J. Mujic F. Taub N. A. Hunt B. J. Hughes G. R. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med: 1995; 332 15 993 997
16. Schulman S. Svenungsson E. Granqvist S.; Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med: 1998; 104 04 332 338
17. Kearon C. Akl E. A. Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood: 2014; 123 12 1794 1801
18. Kearon C. Akl E. A. Ornelas J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest: 2016; 149 02 315 352
19. Pengo V. Ruffatti A. Legnani C., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost: 2010; 8 02 237 242
20. Ruiz-Irastorza G. Hunt B. J. Khamashta M. A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum: 2007; 57 08 1487 1495
21. Muñoz-Rodriguez F. J. Font J. Cervera R., et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum: 1999; 29 03 182 190
22. Ruiz-Irastorza G. Khamashta M. A. Hunt B. J. Escudero A. Cuadrado M. J. Hughes G. R. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med: 2002; 162 10 1164 1169
23. Crowther M. A. Ginsberg J. S. Julian J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med: 2003; 349 12 1133 1138
24. Ames P. R. Ciampa A. Margaglione M. Scenna G. Iannaccone L. Brancaccio V. Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: an 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia. Thromb Haemost: 2005; 93 04 694 699
25. Prandoni P. Simioni P. Girolami A. Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation. Thromb Haemost: 1996; 75 05 859
26. Girón-González J. A. García del Río E. Rodríguez C. Rodríguez-Martorell J. Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol: 2004; 31 08 1560 1567
27. Derksen R. H. de Groot P. G. Kater L. Nieuwenhuis H. K. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis: 1993; 52 09 689 692
28. Rance A. Emmerich J. Fiessinger J. N. Anticardiolipin antibodies and recurrent thromboembolism. Thromb Haemost: 1997; 77 01 221 222
29. Ginsberg J. S. Wells P. S. Brill-Edwards P., et al. Antiphospholipid antibodies and venous thromboembolism. Blood: 1995; 86 10 3685 3691
30. Finazzi G. Marchioli R. Brancaccio V., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost: 2005; 3 05 848 853
31. Levine S. R. Brey R. L. Tilley B. C., et al. APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA: 2004; 291 05 576 584
32. Gardiner C. Hills J. Machin S. J. Cohen H. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus: 2013; 22 01 18 25
33. Keeling D. Mackie I. Moore G. W. Greer I. A. Greaves M.; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol: 2012; 157 01 47 58
34. Holbrook A. Schulman S. Witt D. M., et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 e152S e184S
35. Ruiz-Irastorza G. Cuadrado M. J. Ruiz-Arruza I., et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus: 2011; 20 02 206 218
36. Tripodi A. Chantarangkul V. Clerici M. Negri B. Galli M. Mannucci P. M. Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. Br J Haematol: 2001; 115 03 672 678
37. Pengo V. Tripodi A. Reber G., et al. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost: 2009; 7 10 1737 1740
38. Martin K. Beyer-Westendorf J. Davidson B. L. Huisman M. V. Sandset P. M. Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost: 2016; 14 06 1308 1313
39. Kubitza D. Becka M. Zuehlsdorf M. Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol: 2007; 47 02 218 226
40. Heidbuchel H. Verhamme P. Alings M., et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace: 2015; 17 10 1467 1507
41. Makris M. Van Veen J. J. Tait C. R. Mumford A. D. Laffan M.; British Committee for Standards in Haematology. Guideline on the management of bleeding in patients on antithrombotic agents. Br J Haematol: 2013; 160 01 35 46
42. Gulseth M. P. Overview of direct oral anticoagulant therapy reversal. Am J Health Syst Pharm: 2016; 73 (10, Suppl 2): S5 S13
43. Lanas A. García-Rodríguez L. A. Polo-Tomás M., et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol: 2009; 104 07 1633 1641
44. Connolly S. J. Ezekowitz M. D. Yusuf S., et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med: 2009; 361 12 1139 1151
45. Patel M. R. Mahaffey K. W. Garg J., et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med: 2011; 365 10 883 891
46. Granger C. B. Alexander J. H. McMurray J. J., et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2011; 365 11 981 992
47. Giugliano R. P. Ruff C. T. Braunwald E., et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2013; 369 22 2093 2104
48. Schulman S. Kearon C. Kakkar A. K., et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med: 2009; 361 24 2342 2352
49. Bauersachs R. Berkowitz S. D. Brenner B., et al. EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med: 2010; 363 26 2499 2510
50. Büller H. R. Prins M. H. Lensin A. W., et al. EINSTEIN-PE Investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med: 2012; 366 14 1287 1297
51. Büller H. R. Décousus H. Grosso M. A., et al. Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med: 2013; 369 15 1406 1415
52. Agnelli G. Buller H. R. Cohen A., et al. AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med: 2013; 369 09 799 808
53. Cohen H. Arachchillage D. R. Middeldorp S. Beyer-Westendorf J. Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost: 2016; 14 08 1673 1676
54. Beyer-Westendorf J. Michalski F. Tittl L., et al. Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting. Thromb Haemost: 2016; 116 04 651 658
55. Schaefer J. K. McBane R. D. Black D. F. Williams L. N. Moder K. G. Wysokinski W. E. Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost: 2014; 112 05 947 950
56. Win K. Rodgers G. M. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol: 2014; 89 10 1017
57. Son M. Wypasek E. Celinska-Lowenhoff M. Undas A. The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases. Thromb Res: 2015; 135 05 1035 1036
58. Noel N. Dutasta F. Costedoat-Chalumeau N., et al. Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmun Rev: 2015; 14 08 680 685
59. Signorelli F. Nogueira F. Domingues V. Mariz H. A. Levy R. A. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol: 2016; 35 03 801 805
60. Unlu O. Cohen H. Cuadrado M. J., et al; Antiphospholipid syndrome alliance for clinical trials & international networking registry analysis: direct oral anticoagulant use among antiphospholipid syndrome patients. [abstract]. Arthritis Rheumatol 2016;68:(Suppl 10) Available at: http://acrabstracts.org/abstract/antiphospholipid-syndrome-alliance-for-clinical-trials-international-networking-registry-analysis-direct-oral-anticoagulant-use-among-antiphospholipid-syndrome-patients/. Accessed January 5, 2017
61. Sciascia S. Breen K. Hunt B. J. Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagul Fibrinolysis: 2015; 26 04 476 477
62. Betancur J. F. Bonilla-Abadía F. Hormaza A. A. Jaramillo F. J. Cañas C. A. Tobón G. J. Direct oral anticoagulants in antiphospholipid syndrome: a real life case series. Lupus: 2016; 25 06 658 662
63. Bachmeyer C. Elalamy I. Rivaroxaban as an effective treatment for recurrent superficial thrombophlebitis related to primary antiphospholipid syndrome. Clin Exp Dermatol: 2014; 39 07 840 841
64. Cohen H. Hunt B. J. Efthymiou M., et al. RAPS trial investigators. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol: 2016; 3 09 e426 e436
65. Cohen H. Doré C. J. Clawson S., et al. RAPS Trial Protocol Collaborators. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. Lupus: 2015; 24 10 1087 1094
66. Hemker H. C. Al Dieri R. De Smedt E. Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost: 2006; 96 05 553 561
67. Hemker H. C. Giesen P. Al Dieri R., et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb: 2003; 33 01 4 15
68. Al Dieri R. de Laat B. Hemker H. C. Thrombin generation: what have we learned? Blood Rev: 2012; 26 05 197 203
69. Váradi K. Turecek P. L. Schwarz H. P. Thrombin generation assay and other universal tests for monitoring haemophilia therapy. Haemophilia: 2004; 10 (Suppl 2): 17 21
70. Mancuso M. E. Chantarangkul V. Clerici M., et al. The thrombin generation assay distinguishes inhibitor from non-inhibitor patients with severe haemophilia A. Haemophilia: 2016; 22 04 e286 e291
71. Besser M. Baglin C. Luddington R. van Hylckama Vlieg A. Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost: 2008; 6 10 1720 1725
72. Tripodi A. The history of phenotypic testing in thrombosis and hemostasis. Semin Thromb Hemost: 2008; 34 07 585 592
73. Dargaud Y. Trzeciak M. C. Bordet J. C. Ninet J. Negrier C. Use of calibrated automated thrombinography +/- thrombomodulin to recognise the prothrombotic phenotype. Thromb Haemost: 2006; 96 05 562 567
74. Hron G. Kollars M. Binder B. R. Eichinger S. Kyrle P. A. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA: 2006; 296 04 397 402
75. Devreese K. Peerlinck K. Arnout J. Hoylaerts M. F. Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography. Thromb Haemost: 2009; 101 01 185 196
76. Devreese K. Peerlinck K. Hoylaerts M. F. Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants. Blood: 2010; 115 04 870 878
77. Efthymiou M. Lawrie A. S. Mackie I., et al. Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome. Thromb Res: 2015; 135 06 1191 1197
78. Arachchillage D. R. Efthymiou M. Mackie I. J. Lawrie A. S. Machin S. J. Cohen H. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. Thromb Res: 2015; 135 02 388 393
79. Brodin E. Seljeflot I. Arnesen H. Hurlen M. Appelbom H. Hansen J. B. Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment. Thromb Res: 2009; 123 04 573 579
80. Gerotziafas G. T. Dupont C. Spyropoulos A. C., et al. Differential inhibition of thrombin generation by vitamin K antagonists alone and associated with low-molecular-weight heparin. Thromb Haemost: 2009; 102 01 42 48
81. Graff J. von Hentig N. Misselwitz F., et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol: 2007; 47 11 1398 1407
82. Perzborn E. Strassburger J. Wilmen A., et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct Factor Xa inhibitor. J Thromb Haemost: 2005; 3 03 514 521
83. Samama M. M. Mendell J. Guinet C. Le Flem L. Kunitada S. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res: 2012; 129 04 e77 e82
84. Herrmann R. Thom J. Wood A. Phillips M. Muhammad S. Baker R. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost: 2014; 111 05 989 995
85. Green L. Lawrie A. S. Patel S., et al. The impact of elective knee/hip replacement surgery and thromboprophylaxis with rivaroxaban or dalteparin on thrombin generation. Br J Haematol: 2010; 151 05 469 476
86. Eerenberg E. S. Kamphuisen P. W. Sijpkens M. K. Meijers J. C. Buller H. R. Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation: 2011; 124 14 1573 1579
87. Gerotziafas G. T. Elalamy I. Depasse F. Perzborn E. Samama M. M. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost: 2007; 5 04 886 888
88. Wan H. Yang Y. Zhu J., et al. An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban. Blood Coagul Fibrinolysis: 2016; 27 08 882 885
89. Serebruany V. Sani Y. Lynch D., et al. Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke. J Thromb Thrombolysis: 2012; 33 01 22 27
90. Kamisato C. Furugohri T. Morishima Y. A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: Possible mechanisms of paradoxical enhancement of thrombin generation. Thromb Res: 2016; 141 77 83
91. Tripodi A. Padovan L. Veena C. Scalambrino E. Testa S. Peyvandi F. How the direct oral anticoagulant apixaban affects thrombin generation parameters. Thromb Res: 2015; 135 06 1186 1190
92. Kubitza D. Becka M. Voith B. Zuehlsdorf M. Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther: 2005; 78 04 412 421
93. Arachchillage D. R. Mackie I. J. Efthymiou M. Isenberg D. A. Machin S. J. Cohen H. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost: 2015; 13 07 1264 1273
94. van Os G. M. de Laat B. Kamphuisen P. W. Meijers J. C. de Groot P. G. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost: 2011; 9 08 1657 1659
95. Merriman E. Kaplan Z. Butler J. Malan E. Gan E. Tran H. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost: 2011; 105 02 385 386
96. Martinuzzo M. E. Barrera L. H. D'adamo M. A. Otaso J. C. Gimenez M. I. Oyhamburu J. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin. Int J Lab Hematol: 2014; 36 02 144 150
97. Eby C. Novel anticoagulants and laboratory testing. Int J Lab Hematol: 2013; 35 03 262 268
98. Halbmayer W. M. Weigel G. Quehenberger P., et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med: 2012; 50 09 1601 1605
99. Arachchillage D. R. Mackie I. J. Efthymiou M., et al. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism. J Thromb Haemost: 2016; 14 11 2177 2186